Citations

Clear

9383 citation(s) found for "Thomas, PS".

Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
Stish, Bradley J. , Mazza, Gina L. , Nauseef, Jones T. , Humeniuk, Michael, Smith, Thomas J. , Tofthagen, Cindy, Pardo, D.A. Diaz, Chay, Christopher H., Huang, Andrew Jonathan, Naha, Kushal , Tagawa, Scott T., Chow, Selina , Ruddy, Kathryn, Lustberg, Maryam B. , Adams-Campbell, Lucile L., Novotny, Paul J. , Loprinzi, Charles L. , Tofthagen, Cindy , Diaz, Dayssy A. , Tofthagen, Cindy S , Sebastian, Nikhil T , Huang, Andrew J , Tagawa, Scott T , Ruddy, Kathryn J , Smith, Thomas J , Mazza, Gina L , Nauseef, Jones T , Lustberg, Maryam , Tagawa, Scott T. , Ruddy, Kathryn J. , Adams-Campbell, Lucile L.

Mayo Clinic

Journal of Clinical Oncology | January 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1198-1205

10.1200/jco-25-01486 | PMID 41587370 Get It

PURPOSE Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. PATIENTS AND METHODS Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash–Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. RESULTS Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 ( P = .02), and 6.89 ( P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 ( P = .07), and 13.95 ( P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg ( P = .042) and 5 mg ( P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo. CONCLUSION Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.
Deep learning to predict left ventricular hypertrophy from the electrocardiogram
Naderi, Hafiz , Kaplan, Thomas, Duijvenboden, Stefan van , Pujadas, Esmeralda Ruiz , Aung, Nay, Chahal, C Anwar A, Lekadir, Karim , Chamling, Bishwas , Dörr, Marcus , Markus, Marcello R P , Petersen, Steffen E, Ramírez, Julia, Munroe, Patricia B, Chahal, C. Anwar A. , Munroe, Patricia B. , Aung, Nay , Lekadir, Karim , Markus, Marcello Ricardo Paulista , van Duijvenboden, Stefan , Aung, Nay , Chahal, Choudhary Anwar A , Petersen, Steffen E , Ramírez, Julia , Munroe, Patricia B , Kaplan, Thomas M. , Petersen, Steffen E.

Mayo Clinic

Europace | January 23, 2026 | Volume: 28 | Issue: 2 | Pages: No page available

10.1093/europace/euag015 | PMID 41589068 Get It

Abstract Aims Left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular disease. We previously compared supervised machine learning techniques to classify cardiac magnetic resonance (CMR)-derived LVH using electrocardiogram (ECG) and clinical variables in 37 534 UK Biobank participants, obtaining an area under the receiving operating curve (AUROC) of 0.85, but with limited specificity and requiring external validation. In this study, we develop a deep learning (DL) model to improve classification with external evaluation in the Study of Health in Pomerania (SHIP). Methods and results We analysed 12-lead ECGs of 48 835 participants from the UK Biobank imaging study. The dataset was split into a training set (70%), validation set (15%), and test set (15%) for performance evaluation. The model architecture was a fully convolutional network, for which the input was the participants’ median ECG and clinical variables and the predicted indexed left ventricular mass (iLVM) as the output. A subsequent logistic regression model was used to recalibrate iLVM predictions. In UK Biobank, 717 (1.5%) participants had CMR-derived LVH and the AUROC for the DL model was 0.97. The ECG components most predictive of LVH were the QRS complex and ventricular rate. The DL model outperformed our supervised algorithms, previous DL modelling efforts and clinical ECG benchmarks. There was modest generalizability of the DL model to 1423 participants in SHIP (AUROC 0.78), with differences in clinical profile, ECG acquisition, and CMR labelling as important factors. Conclusion Our findings support the feasibility of scalable DL-based screening tools for the prediction of LVH from the ECG, whilst highlighting the need for model development using larger datasets with greater diversity to ensure generalizability.
Redefining Evidence‐Based Practice Through Patient Values: A Theoretical Innovation for Person‐Centered, Value‐Based Care
Shapiro, S , Logvinov, Ilana I. , Thomas, Rachel McMahan , Shapiro, Sandra D , Logvinov, Ilana

Mayo Clinic

Journal of Evaluation in Clinical Practice | January 22, 2026 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/jep.70344 | PMID 41569875 Get It

ABSTRACT Rationale Before evidence‐based practice (EBP) was formally adopted, healthcare decisions relied on critical thinking and clinical judgment informed by disciplinary knowledge, theory, and research, but lacked full integration of patient values with clinical expertise. Sackett et al. redefined EBP as the integration of the best available evidence, clinical expertise, and patient values. This framework has been embraced by nursing and other healthcare disciplines, embedding EBP into education, clinical protocols, and quality improvement efforts. Despite widespread adoption, traditional conceptualizations prioritize empirical evidence above patient values, potentially undermining individualized care. Aims and Objectives This paper proposes a reconceptualization that places patient and client values—their why —at the center of EBP, inspired by Simon Sinek's Golden Circle model which emphasizes starting with purpose to influence behavior effectively. Prioritizing the patient's values before incorporating empirical evidence into a care plan ensures that care aligns with their personal goals and definitions of health, fostering therapeutic relationships and supporting meaningful behavior change. Methods A conceptual analysis was conducted using Simon Sinek's Golden Circle model as a guiding framework. This model emphasizes starting with purpose to influence behavior effectively. The analysis explores how integrating patient values first, followed by empirical evidence and clinical expertise, can operationalize person‐centered EBP. Results The reconceptualized framework positions patient values as the foundation of care planning. By aligning interventions with patients' personal goals and values first, clinicians can strengthen therapeutic relationships and support individualized care. Conclusion Effective nursing clinicians and leaders must embrace this patient‐first approach to truly operationalize person‐centered, evidence‐based care that respects the diverse needs and motivations of patients.
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
Folprecht, G., Varghese, Anna M. , Gutiérrez, Martín , Noel, Marcus Smith , Chen, Eric, Dayyani, Farshid, Davis, S Lindsey, BasuMallick, Atrayee, Garrido-Laguna, Ignacio, Osawa, Mayu, O’Brien, Shaun, Novosiadly, Ruslan D., Xu, Ke, Greenawalt, Danielle , Dutta, Santanu, Victor, Christina Twyman Saint, Lenz, Heinz-Josef, Folprecht, Gunnar , Chen, Eric , Osawa, Mayu , Le, Dung Thi , Trikalinos, Nikolaos A. , Chen, Eric X. , Dayyani, Farshid , Davis, S Lindsey, Wee, Wen , Garrido‐Laguna, Ignacio , O’Brien, Shaun, Dutta, Santanu , Victor, Christina Twyman-Saint , Lenz, Heinz‐Josef

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 22, 2026 | Volume: 14 | Issue: 1 | Pages: e011284

10.1136/jitc-2024-011284 | PMID 41571299 Get It

Background Cysteine–cysteine chemokine receptors 2 (CCR2) and 5 (CCR5) contribute to immune suppression in tumor microenvironments. CCR2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), respectively. This phase 1b/2, open-label study evaluated BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy±nivolumab in advanced PDAC or metastatic CRC. Methods Part 1 included patients with metastatic untreated (first-line (1L)) PDAC, 1L CRC, or previously treated (second or third line (2/3L)) microsatellite stable (MSS) CRC. Patients received 2 weeks of BMS-813160 monotherapy (300 mg two times a day, 600 mg once daily, 300 mg once daily, or 150 mg once daily) and then BMS-813160+chemotherapy (gemcitabine+nab-paclitaxel (gem/nabP; 1L PDAC), 5-fluorouracil+leucovorin+irinotecan (FOLFIRI; 1L CRC)), or nivolumab (2/3L MSS CRC). Part 2 included patients with metastatic 1L PDAC or 2L CRC. Patients received BMS-813160 300 mg two times a day+gem/nabP±nivolumab (1L PDAC), BMS-813160 300 mg two times a day or 150 mg once daily+FOLFIRI (2L CRC), or chemotherapy alone. Primary endpoints were safety and pharmacodynamics (Part 1) and efficacy (Part 2). Results In Part 1, 22 of 75 (29%) and 54 of 72 (72%) patients experienced a treatment-related adverse event during monotherapy lead-in and overall, respectively. Two dose-limiting toxicities (rash and pericardial effusion with pericarditis, both grade 3) occurred. In Part 2, patients with 1L PDAC who received BMS-813160 300 mg two times a day+gem/nabP+nivolumab achieved an overall response rate (ORR) of 37% (13/35); the median duration of response (DOR) was 45 weeks (95% CI 26.1 to not evaluable). ORRs with BMS-813160 300 mg two times a day+gem/nabP and gem/nabP alone were 26% (9/35) and 28% (9/32), respectively; median DORs were 121 and 31 weeks, respectively. Progression-free survival rates at 24 weeks were 56% (BMS-813160 300 mg two times a day+gem/nabP+nivolumab), 56% (BMS-813160 300 mg two times a day+gem/nabP), and 50% (gem/nabP). ORRs in 2L CRC were 19% (6/32; BMS-813160 300 mg two times a day+FOLFIRI), 13% (4/32; BMS-813160 150 mg once daily+FOLFIRI), and 27% (7/26; FOLFIRI). Conclusions In 1L PDAC, BMS-813160 300 two times a day+gem/nabP±nivolumab demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clinical efficacy was not demonstrated. Trial registration number NCT03184870 .
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial
Rubin, Mishaela R. , Clarke, B.L. , Khan, Aliya, Schwarz, Peter, Vokes, Tamara , Ahmed, Intekhab, Palermo, Andrea, Cetani, F., Pagotto, Uberto , Zhao, Carol, Ominsky, Michael S. , Lai, Bryant, Ukena, Jenny, Shu, Aimee D , Rejnmark, L, Schwarz, Peter , Palermo, Andrea , Clarke, Bart L , Khan, Aliya A , Schwarz, Peter , Palermo, Andrea , Cetani, Filomena , Pagotto, Uberto , Shu, Aimee D , Rejnmark, Lars , Hofbauer, Lorenz C. , Khan, Aliya , Zhao, Carol, Ukena, Jenny, Rejnmark, Lars

Mayo Clinic

Journal of Bone and Mineral Research | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbmr/zjag013 | PMID 41636590 Get It

Abstract Hypoparathyroidism is an endocrine disease caused by insufficient levels of PTH, which acts directly on bone and kidney and indirectly on the intestine to regulate calcium and phosphate balance. In clinical trials, palopegteriparatide (TransCon PTH) treatment enabled independence from conventional therapy (no active vitamin D, ≤600 mg/d calcium) and maintained serum biochemistries within normal ranges. The current analyses describe patterns of change in BMD, serum bone turnover markers, and serum and urine calcium in adults with chronic hypoparathyroidism treated with palopegteriparatide through 3 years of the PaTH Forward trial. Baseline BMD Z-scores for the LS, TH, FN, and 1/3 distal radius were above zero, indicating bone mass exceeding age-adjusted normative values. BMD decreased from these elevated baseline levels with palopegteriparatide treatment, with larger reductions during the first 26 weeks and modest declines thereafter. Mean BMD Z-scores at week 162 remained above zero for all 4 sites. Participants with lower baseline BMD (Z-scores below −1 and T-scores below −2.5) generally exhibited lesser declines in BMD versus those with higher baseline BMD. Palopegteriparatide treatment was associated with early increases in bone resorption (serum C-terminal telopeptide of type I collagen, CTx) and bone formation (serum procollagen type 1 N-terminal propeptide, P1NP) that peaked at weeks 12 and 26, respectively, followed by declines to levels moderately higher than baseline at week 162. Mean CTx and P1NP in the overall population and the subgroup of postmenopausal women were below their upper limits of normal from weeks 58-162. At week 162, mean serum and median urine calcium remained within normal ranges and 91% of participants were independent from conventional therapy. These results suggest that long-term palopegteriparatide therapy in adults with chronic hypoparathyroidism gradually returns the skeleton toward its natural state thereby enhancing the skeleton’s contribution to calcium homeostasis.
Core outcomes in nerve surgery: development of a core outcome set for lateral femoral cutaneous neuropathy
Wilson, Thomas J., Ali, Zarina S., Desai, Ketan, Garozzo, Debora, Guedes, Fernando, Heinen, Christian P. G., Hong, Jennifer , Jacques, Line G., Jitpun, Ekkapot , Kretschmer, Thomas , Mahan, Mark A., Midha, Rajiv, Puffer, Ross C. , Rasulic, L., Ray, Wilson Z., Rizk, Elias , Rodriguez-Aceves, Carlos A., Shapira, Yuval, Spinner, Robert J., Zager, Eric L. , Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Dengler, Nora F. , Guedes, Fernando , Heinen, Christian , Jacques, Line , Mahan, Mark A , Midha, Rajiv, Pondaag, Willem , Rasulić, Lukas , Ray, Wilson Z. , Rodríguez-Aceves, Carlos Alberto , Saadeh, Yamaan S. , Socolovsky, Mariano , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 5 | Pages: 1224-1232

10.3171/2025.8.jns251142 | PMID 41569664 Get It

OBJECTIVE Core outcome sets (COSs) are needed to promote data consistency across studies as well as data synthesis and comparability. The aim of the current study was to use a modified Delphi process to develop a COS for lateral femoral cutaneous neuropathy (LFCN), hereafter COS-LFCN. METHODS A 5-stage approach was used to develop the COS-LFCN: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. This study followed the Core Outcome Set - STAndards for Development, (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 25 participants, all neurological surgeons, representing 14 countries. The final COS-LFCN consisted of 41 factors and outcomes covering domains of demographics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 12 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS for LFCN and provided definitions, methods of implementation, and time points for assessment. The COS-LFCN should serve as the minimum data to be collected in all future neurosurgical studies on LFCN. Incorporation of this COS will help improve consistency in reporting, data synthesis and comparability, and minimize outcome reporting bias.
Outcomes of Hip Arthroscopy in Patients With Acetabular Cysts: A Multicenter Matched Controlled Study From the MASH Study Group
Matsuda, Dean, Wolff, Andrew B. , Nho, Shane, Christoforetti, John J. , Salvo, John P. , Martin, RobRoy L., McGovern, Ryan P. , Silk, Richard J., Ishimoto, Allysa, Ko, Brandon, Matsuda, Dean K. , Martin, RobRoy L. , Carreira, Dominic S.

Mayo Clinic

The American Journal of Sports Medicine | January 21, 2026 | Volume: 54 | Issue: 2 | Pages: 424-430

10.1177/03635465251405731 | PMID 41562523 Get It

Background: Some studies have reported more severe chondral pathology and less successful hip arthroscopic outcomes in patients with acetabular subchondral cysts. Purpose/Hypothesis: The purpose of this study was to report multicenter arthroscopic outcomes of patients with and without acetabular bone cysts. It was hypothesized that patients with acetabular cysts would demonstrate inferior outcomes at minimum 2-year follow-up compared with patients without acetabular cysts. Study Design: Cohort study; Level of evidence, 3. Methods: A multicenter matched-pair study was performed across 6 medical centers with data from a large prospectively collected database. Inclusion criteria were adult patients who had undergone primary unilateral hip arthroscopy for femoroacetabular impingement syndrome (FAIS). The study group was defined by the presence of a superolateral acetabular subchondral cyst on preoperative imaging. A control group was matched on age; sex; body mass index (BMI); lateral center-edge angle (LCEA); alpha angle; arthroscopic treatments of femoroplasty, acetabuloplasty, and labral treatment (ie, repair, reconstruction, or debridement); Beck chondral grade; and minimum 2-year outcomes using visual analog scale (VAS) for pain, International Hip Outcome Tool-12 (iHOT-12), minimal clinically important difference (MCID), substantial clinical benefit (SCB), and Patient Acceptable Symptom State (PASS). Results: The study included 82 patients, of whom 41 composed the study group and 41 served as matched control patients. The study group had a mean age of 42.16 ± 11.26 years with 48.78% women and a mean BMI of 26.51 ± 4.31 kg/m 2 . Mean LCEA was 33.55°± 6.30°, and mean alpha angle was 70.22°± 9.71°. Mean Beck chondral grade was 2.59 ± 1.27 in the study group and 2.70 ± 0.95 in the matched control group ( P = .72). Two-year mean postoperative iHOT-12 scores for the study and control groups were 69.49 ± 24.51 and 73.24 ± 25.16, respectively ( P = .38), whereas mean postoperative VAS scores for pain were 18.84 ± 18.17 and 20.74 ± 21.39, respectively ( P = .70). The study group reached MCID in 82.93%, SCB in 58.54%, and PASS in 65.85% and were similar to those of the control group. Conclusion: Patients undergoing arthroscopic surgery for FAIS with acetabular cysts had similarly successful outcomes as patients without acetabular cysts. Acetabular subchondral cysts may not be a contraindication to hip arthroscopy in patients with FAIS who would otherwise be indicated for this surgery.
P0577 real world durability of response and remission with upadacitinib in Ulcerative Colitis: a multi-centre study
Huang, K, Chandnani, Arun, Samaan, Soleil , Tan, Tao , Ramesh, P R, Conlon, Caroline , Klein, J, Reddy, Nikhil, Ayoub, M, CervantesLimon, G, Myers, Mark R., Bucaram, M, Lieto, Stephen, Scalzo, Nicholas , Cohen, B, Ciorba, Mathew A., Shukla, R. , Wright, M, Xu, A T, Chowla, Navreet , Ogholikhan, Sina, Kujawski, M, Dulaney, David , Fenster, M, Benson, C, Alhobayb, T, Berinstein, J, Shivashankar, Raina , Bishu, S, Patel, A, Ungaro, R, Johnson, A, Pekow, J R, Samaan, S, Ayoub, Malek , Myers, M, Bucaram, Martha R., Mohamed, Islam , Wright, Michael C., Xu, Anthony, Kujawski, Michelle, Fenster, Marc, Benson, Caroline, Alhobayb, Tamara Y. , Berinstein, Jeffrey , Bishu, Shrinivas , Ungaro, Ryan C. , Pekow, Joel , Yarur, Andrés , Deepak, Parakkal

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.758 Get It

Abstract Background We aimed to describe the real-world durability of clinical and endoscopic outcomes of upadacitinib (UPA) in ulcerative colitis (UC). Methods We retrospectively analyzed an ongoing multi-center cohort of UC patients(pts) in the United States who were started on UPA for active disease. Primary outcome was clinical remission at 1yr assessed by partial Mayo score(pMS)(resolution of all UC related symptoms and physician global assessment). Secondary outcomes assessed at various timepoints, including after re-escalation, included clinical response(&gt;50%reduction in symptoms utilizing the pMS), endoscopic response (Mayo endoscopic score≤1or absence of erosions/ulcerations) and histological remission(defined as normal or chronic inactive). Durable secondary outcomes achieved at both 6months and at 1yr and beyond were also assessed. Descriptive statistics were performed. Adverse events(AEs) investigated included cardiovascular events and herpes zoster (HZ). Results 416pts were included(Table 1) with median values for age at initiation of36.00yrs(range27-48), disease duration7.00yrs(range3-14)and follow-up 993days(IQR,672-1103), with206(49.52%)with follow-up at 1yr or beyond. Of these, 66.1%had extensive colitis. Induction duration was8wks in 86.5%and16wks in 4.8 %(20/416). Most received an induction dose of45mg(97.1%)and maintenance dose of30mg(85.8%). Among the evaluable population at1yr and beyond, 62.5%(45/80)were in clinical remission, 75.9%(22/29)in endoscopic response with58.6%(17/29) in remission and66.6%(20/30)in histological remission. At 6months, clinical remission was51.6%(42/93), endoscopic response was 75%(24/32) of which43.75%(14/32)were in remission and histologic remission was seen in 40.8%(20/49).Durable secondary outcomes of clinical remission were seen in 71.4%(30/42), endoscopic improvement in 45.8%(11/24), and histologic remission in35%(7/20). Re-escalation to 45mg occurred in 35pts, of which48.6%(17/35)were re-escalated due to incomplete induction clinical response with all achieving response(11 in remission). The rest(18/35)were re-escalated for clinical relapse after initial remission where72.2%(13/18)were able to recapture remission. After re-escalation,54.3%(19/35)continued on 45mg daily. AEs were reported in12.7%with HZ in 7pts(2.1%). One pt aged53yrs had an episode of TIA after 1yr on UPA at 15mg, without pre-existing cardiovascular risk factors and UPA use is ongoing at the same dose. There were no reported episodes of worsening of pre-existing cardiovascular disease or DVT/PE. Conclusion UPA is durably effective and safe in a real-world clinical setting with re-escalation to 45mg capturing response in a majority of the pts. Ongoing recruitment will provide further evidence on long term effectiveness and safety. Conflict of interest: Ms. Huang, Katherine: No conflict of interest Chandnani, Arun: No conflict of interest Samaan, Sami: None Tan, Tingyi: I have no conflict of interests to declare. Ramesh, Prajith Raj: None Conlon, Caroline: No conflict of interest Klein, Jeremy: None Reddy, Nikhil: No conflict of interest Ayoub, Malek: None Cervantes Limon, Gabriela: none Myers, Melissa: None Bucaram, Martha: No conflict of interest Lieto, Stephen: No conflict of interest Scalzo, Nicholas: No conflict of interest Cohen, Benjamin: Abbvie - consulting and speaking ALPCO - consulting J & J Innovative Medicine - consulting Takeda - consulting and speaking Emmes Biopharma Services LLC - DSMB Pfizer - consulting Mohamed, Islam: nothing to declare Ciorba, Matthew: Advisory Board: Janssen, AbbVie, Pfizer, Geneoscopy Consulting: Janssen, AbbVie, Pfizer, Geneoscopy Grant contracts: Janssen, Pfizer, Incyte Shukla, Richa: Speakers bureau - Abbvie and Lilly Wright, Michael: None Xu, An Tao: No conflict of interest Chowla, Navreet: No conflict of interest Ogholikhan, Sina: Abbvie Medical Director Kujawski, Michelle: Abbvie Scientific Director Dulaney, David: Speaker bureau - Regeneron Speaker bureau - Sanofi Speaker bureau - Takeda Speaker bureau - Eli Lilly Fenster, Marc: none Benson, Caroline: No conflict of interest Alhobayb, Tamara: No conflict of interest Berinstein, Jeffrey: No conflict of interest Shivashankar, Raina: Abbvie and BMS - speaker bureau Janssen and Celltrion - grant for IBD fellowship funding Pfizer - consultant Bishu, Shrinivas: None Patel, Anish: speaker: abbvie, J & J, Lilly, BMS, Pfizer, Phathom, Takeda consultant: abbvie Ungaro, Ryan: Personal Fees: AbbVie, Bristol Myers Squibb, Genentech, Lilly, Pfizer, Janssen, Takeda Johnson, Amanda: Research grant: Abbvie, Spyre Therapeutics Pekow, Joel R.: CVS Health - Consulting Abbvie, Eli Lilly, Pfizer, Johnson and Johnson - Stocks Yarur, Andres: Personal Fees: Consultant for Takeda, Pfizer, Roche, Merck, Abbvie, Eli Lilly. Bristol Myers Squibb, Celltrion, Johnson and Johnson. Deepak, Parakkal: Parakkal Deepak has received research support under a sponsored research agreement unrelated to the data in the abstract from AbbVie, Johnson and Johnson, Sanofi, Merck, Teva, Direct Biologics, Tr1x, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Roche Genentech, Eli Lilly, AstraZeneca, Spyre and Agomab, has received consulting fees from Johnson and Johnson, Abbvie, Merck, Sobi, Celltrion, Fresenius Kabi, Asahi Kasei Pharma, Sandoz and CorEvitas, LLC and has served on the board of the Srategic Alliance for Intercultural Advocacy in GI.
Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN
Afolaranmi, Oluwasegun, Guiterrez, George, Oyewole, Adewale Isaiah, Ebekue, Dorcas Olaide, Adegbite, Zainab, Awe, Clement, Ogunniyi, Titilope, Opeyemi, Akinlusi, Uwechue, Frances I, Sherman, Dan, Lambert, Clara N. , Adedayo, Joseph, Diaz, Kristina, Christian, Elizabeth Nicole, Akin-Adigun, Olufemi, Okeke, Sophia , Knapp, Gregory, Dare, Anna Yunita, Aduloju, Toluwanimi, Akinwumi, Moyinoluwa, Nwogu, Chukwumere E., Hirschhorn, Lisa R, Adin-Cristian, Andrei, Iwuji, Chinenye , Ilegbune, Oge, Jimoh, Mutiu , Chugani, Bindiya , Oputa, Olise, French, Dustin D. , Ackermann, Ron, Murphy, Robert, Seddoh, Anthony Theophilus, Kingham, Peter Thomas, Lumati, Juliet S., Afolaranmi, Oluwasegun , Afolaranmi, Oluwasegun , Lumati, Juliet S , Sohail, Amir Humza , Wuraola, Funmilola Olanike , Caputo, Matthew , Gutierrez, George A., Nwankwo, Chinyere, Sherman, Daniel, Abdulkareem, Fatimah Biade , Akingbola, Adewunmi , Knapp, Gregory , Dare, Anna, Kohli-Lynch, Ciaran Navin , Chen, Ruohui , Nwogu, Chukwumere E. , Hirschhorn, Lisa R. , Alani, Jimoh Mutiu, Murthy, Shilpa Shree , Ackermann, Ronald T. , Murphy, Robert L. , Kingham, T. Peter , Alatise, Olusegun Isaac

Mayo Clinic

No container title available | January 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7686399/v1 | PMID 41646304 Get It

Abstract Background: As with most Sub-Saharan African countries, Nigeria has a rising incidence of cancer, with disproportionate mortality rates. The financial burden of cancer care often results in catastrophic healthcare spending, leading to treatment refusal, disruption, and discontinuation. This is particularly significant in Nigeria, where nearly all patients are uninsured, and out-of-pocket costs often exceed households’ ability to pay. Financial Navigation Programs (FNPs) have been shown to mitigate treatment-related financial toxicity in cancer care and reduce treatment abandonment, but there is a paucity of high-quality data on this intervention in resource-constrained settings. Here, we present a randomized controlled trial to evaluate the impact of a novel FNP in Nigeria. Methods: We designed the COST-FIN trial, a multi-site pragmatic single-blinded randomized controlled trial of newly diagnosed (<6 weeks from diagnosis) adults (≥18 years) with breast, colorectal, or prostate cancer at two tertiary cancer centers in Nigeria. Participants (n=200) will be randomized (1:1) to either the intervention (FNP) or the control arm and followed for 12 months. Data on key individual, treatment, and financial parameters will be collected via structured interviews and chart abstraction at baseline, 3, 6, and 12-month follow-up. In addition, participants randomized to the FNP will receive a tailored financial literacy assessment, financial planning support, and enhanced access to resources by trained financial navigators. Primary and secondary outcomes are Financial Catastrophe (FC) and Financial Distress (FD), respectively. Exploratory outcomes will include cost-related non-adherence and cost-effectiveness of the program. An interim analysis will be conducted when 50% of the estimated accruals reach 6 months of follow-up, with crossover if compelling evidence of benefit is demonstrated at that time point. All participants will be followed for 12 months from recruitment. Discussion: This first-of-its-kind study will provide evidence on the role of FNP in potentially eliminating financial barriers to cancer care in Nigeria. Given the country’s renewed interest in cancer control through the passage of the National Cancer Control Plan, findings from this study have the potential to influence policy reform and set the stage for further studies to evaluate the scalability and implementation of similar interventions in resource-limited settings. Trial registration : ClinicalTrials.gov NCT06630962. Oct 8, 2024 (https://clinicaltrials.gov/study/NCT06630962)
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
Taplin, Mary-Ellen, Riaz, Irbaz Bin , Rumble, R. Bryan , Naqvi, Syed Arsalan Ahmed , Hope, MD Thomas A., Dias, Mariane Fontes , He, Huan, Hotte, Sebastién J. , Emamekhoo, Hamid, Murad, M. Hassan, Celano, Paul , Kungel, Terry M. , Hentzen, Steve, Serzan, Michael , Parikh, Rahul A., Murad, M. Hassan , Hope, Thomas A. , Emamekhoo, Hamid , Dias, Mariane Sousa Fontes , Hope, Thomas A , Emamekhoo, Hamid , Murad, M Hassan , Serzan, Michael Thomas , Parikh, Rahul A , He, Huan , Riaz, Irbaz B , Hotte, Sebastien J , Rumble, R Bryan , Taplin, Mary‐Ellen , Kungel, Terry

Mayo Clinic

Journal of Clinical Oncology | January 20, 2026 | Volume: 44 | Issue: 6 | Pages: No page available

10.1200/jco-25-02693 | PMID 41557978 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found at www.asco.org/genitourinary-cancer-guidelines .